NR4A1 and neoplasm: In HR+ patients, a prediction algorithm including tumor size, nodal status, tumor grade, proliferative markers, and levels of hormone receptor expression are used to calculate the likelihood of tumor recurrence risk and further support decision making for adjuvant treatments [2].